Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India
Rattachement africain : in, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The childhood burden of disease attributable to Streptococcus pneumoniae is particularly high in India. The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in a randomized, active-controlled, double-blind trial conducted at 12 sites in India. METHODS: Healthy infants received PCV13 or PCV7 at 6, 10, and 14 weeks of age (infant series) and at 12 months of age (toddler dose), along with routine pediatric vaccinations. Immunoglobulin G responses against the 13 pneumococcal serotypes were evaluated 1 month after the infant series and after the toddler dose. Pertussis and poliomyelitis immune responses were assessed 1 month after the infant series. Safety and tolerability also were assessed. RESULTS: The immunogenicity results for the 7 common serotypes and the concomitant vaccines (whole-cell pertussis and oral poliovirus) were similar for subjects receiving PCV13 and subjects receiving PCV7. Immune responses to the 6 additional serotypes were higher in the PCV13 group compared with the PCV7 group. PCV13 and PCV7 had similar safety and tolerability profiles. CONCLUSIONS: PCV13 has immunogenicity similar to PCV7 in response to the 7 common serotypes, and has generally higher immunogenicity in response to the 6 additional serotypes. PCV13 may provide added protection against pneumococcal disease caused by the additional 6 serotypes and does not interfere with immune responses to whole-cell pertussis and oral poliovirus vaccines. PCV13 has an acceptable safety profile in both infants and toddlers, comparable with that of PCV7.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India
- Date Crossref
- 01/05/2013
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Jaslok Hospital pays non établi dans la noticeÉtablissement de santé
-
Pfizer (United Kingdom) pays non établi dans la noticeEntreprise
-
Bharati Vidyapeeth (Deemed to be University) pays non établi dans la noticeUniversité ou école supérieure
-
King Edward Memorial Hospital Research Centre pays non établi dans la noticeÉtablissement de santé
-
Pfizer (India) pays non établi dans la noticeEntreprise
-
Pfizer (United States) pays non établi dans la noticeEntreprise
-
Kanchi Kamakoti CHILDS Trust Hospital pays non établi dans la noticeÉtablissement de santé
-
Medical Research Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
The CHILDS Trust Medical Research Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Christian Medical College Department of Child Health pays non établi dans la noticeUniversité ou école supérieure
-
St.John's Medical College Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Bharati Vidyapeeth University Medical College pays non établi dans la noticeUniversité ou école supérieure
Jaslok Hospital, Pfizer (United Kingdom) et Bharati Vidyapeeth (Deemed to be University), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.